Press Releases

Date Title Link to PDF file
Sept. 3, 2014 RuiYi Appoints Mark Saad Chief Financial Officer
PDF File
June 11, 2014 RuiYi and iHuman Institute Form Collaboration to Identify Novel Antibodies Targeting GPCRs
PDF File
June 11, 2014 RuiYi Closes $4 Million Venture Loan from Silicon Valley Bank
PDF File
March 27, 2014 RuiYi Announces $15 Million Series B to Advance Pipeline of Therapeutic Monoclonal Antibodies Targeting GPCR Receptors
PDF File
May 16, 2013 RuiYi and Genor Biopharma Collaborate on Development in China of RYI-008, a Novel Therapeutic for Autoimmune Diseases and Cancer
PDF File
May 14, 2013 CMC Biologics and RuiYi Enter into an Agreement for Development of a Novel Anti-IL-6 Monoclonal Antibody
PDF File
Oct 4, 2012 RuiYi (formerly Anaphore) and arGEN-X Announce Exclusive Worldwide License Agreement for ARGX-109, a Novel anti-IL-6 Antibody
PDF File
Oct 4, 2012 Anaphore Announces Name Change to RuiYi and New Additions to Shanghai Management Team
PDF File
March 22, 2012 Anaphore Announces Acquisition of RuiYi in Shanghai China for GPCR Biologics Drug Discovery Platform
PDF File
June 20, 2011 Anaphore Appoints Paul A. Grayson President and CEO
PDF File



©2014 RuiYi, All Rights Reserved.